A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Leukemia and Lymphoma

• Publication date

  2014-03-29

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/10428194.2014.907891PMID 24679008PMCID PMC4349217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

  2013cited by this paper
• Evaluation and critical assessment of putative MCL-1 inhibitors

  2013cited by this paper
• Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B

  2012cited by this paper
• What is the European Medicines Agency?

  2012cited by this paper
• Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.

  2012cited by this paper
• Distinct cellular and therapeutic effects of obatoclax in rituximab‐sensitive and ‐resistant lymphomas

  2011cited by this paper
• ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents

  2011cited by this paper
• Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era.

  2011cited by this paper
• Mantle cell lymphoma: the promise of new treatment options.

  2011cited by this paper
• Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis.

  2010cited by this paper
• The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo

  2010cited by this paper
• Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

  2009cited by this paper
• Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.

  2008cited by this paper
• Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004

  2008cited by this paper
• ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.

  2008cited by this paper
• A pivotal role for Mcl-1 in Bortezomib-induced apoptosis

  2008cited by this paper
• A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

  2008cited by this paper
• The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

  2008cited by this paper
• The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

  2007cited by this paper
• Faculty Opinions recommendation of Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.

  2007cited by this paper
• Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.

  2007cited by this paper
• Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics

  2007cited by this paper
• Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis

  2007cited by this paper
• A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150.

  2006cited by this paper
• Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins

  2006cited by this paper
• The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.

  2006cited by this paper
• Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma

  2006cited by this paper
• The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma.

  2006cited by this paper
• Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma.

  2006cited by this paper
• Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity.

  2006cited by this paper
• Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma.

  2005cited by this paper
• Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.

  2005cited by this paper
• Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.

  2005cited by this paper
• The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

  2003cited by this paper
• The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival.

  2003cited by this paper
• Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray.

  2001cited by this paper
• Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

  1999cited by this paper
• [Phase I study].

  1995cited by this paper
• Cyclin D1/bcl‐1 cooperates with myc genes in the generation of B‐cell lymphoma in transgenic mice.

  1994cited by this paper

• BCL-2 and BCL-xL in Cancer: Regulation, Function, and Therapeutic Targeting

  2026cites this paper
• Next-Generation Therapies in Mantle Cell Lymphoma (MCL): The Evolving Landscape in Treatment of Relapse/Refractory After CAR-T Cells

  2025cites this paper
• Anti-breast cancer effects of a novel derivative of biopigment from Serratia marcescens evoked by mitochondrial pathway-mediated apoptosis.

  2025cites this paper
• Medical and Nonmedical Applications of Synthetic Transmembrane Anion Transporters

  2025cites this paper
• Targeting BCL-2 family proteins using BH3 mimetic drugs for cancer therapy: A systematic review of randomized clinical trials

  2024cites this paper
• Targeting regulated cell death pathways in cancers for effective treatment: a comprehensive review

  2024cites this paper
• p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma

  2023cites this paper
• Targeting BCL2 pathways in CLL: a story of resistance and ingenuity

  2023cites this paper
• Prodigiosin: a promising biomolecule with many potential biomedical applications

  2022cites this paper
• Therapeutics targeting BCL2 family proteins

  2022cites this paper
• Targeting Apoptosis in Cancer

  2022cites this paper
• BH3-mimetics: recent developments in cancer therapy

  2021cites this paper
• Targeting Bcl-2 for cancer therapy.

  2021cites this paper
• The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy.

  2021cites this paper
• Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade

  2021cites this paper
• Computational study on novel natural inhibitors targeting BCL2

  2021cites this paper
• Mcl-1 as a "barrier" in cancer treatment: Can we target it now?

  2020cites this paper
• Apoptosis and Cancer

  2020cites this paper
• Targeting Mitochondrial Apoptosis to Overcome Treatment Resistance in Cancer

  2020cites this paper
• BCL-2 Proteins in Pathogenesis and Therapy of B-Cell Non-Hodgkin Lymphomas

  2020cites this paper
• Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.

  2020cites this paper
• Mantle cell lymphoma.

  2020cites this paper
• Novel Apoptosis-Inducing Agents for the Treatment of Cancer, a New Arsenal in the Toolbox

  2019cites this paper
• Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later

  2019cites this paper
• Mantle cell lymphoma: therapeutic options in transplant-ineligible patients

  2019cites this paper
• The chemical biology of apoptosis: Revisited after 17 years.

  2019cites this paper
• Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma.

  2019cites this paper
• Drugs and Clinical Approaches Targeting the Antiapoptotic Protein: A Review

  2019cites this paper
• GX15–070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma

  2019cites this paper
• The rise of apoptosis: targeting apoptosis in hematologic malignancies.

  2018cites this paper
• Cross Talk Between Cellular Redox State and the Antiapoptotic Protein Bcl-2

  2018cites this paper
• Novel imidazopyridine suppresses STAT3 activation by targeting SHP-1

  2018cites this paper
• Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.

  2017cites this paper
• Killing Two Cells with One Stone: Pharmacologic BCL-2 Family Targeting for Cancer Cell Death and Immune Modulation

  2016cites this paper
• Targeting Cell Survival Proteins for Cancer Cell Death

  2016cites this paper
• Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents

  2016cites this paper
• Novel Pharmacotherapies for B-Cell Lymphomas and Leukemias

  2016cites this paper
• Targeting the PI3K/PTEN/AKT/mTOR Pathway in Treatment of Sarcoma Cell Lines.

  2016cites this paper
• Prognosis and outcome of stem cell transplantation for mantle cell lymphoma

  2015cites this paper
• Apoptosis and Cancer

  2015cites this paper
• Design, synthesis and biological evaluation of 3-aryl-rhodanine benzoic acids as anti-apoptotic protein Bcl-2 inhibitors.

  2015cites this paper
• Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside.

  2015cites this paper
• Bortezomib in the treatment of mantle cell lymphoma.

  2015cites this paper
• Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia.

  2015cites this paper
• Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice

  2015cites this paper
• Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia

  2015cites this paper
• Is Bcl-2 a valid target in the treatment of indolent non-Hodgkin lymphoma?

  2014cites this paper
• Bortezomib for the treatment of mantle cell lymphoma

  2014cites this paper